Literature DB >> 15364410

Increased presence of matrix metalloproteinases 2 and 9 in short- and long-term experimental herpes simplex virus encephalitis.

Francisco J Martínez-Torres1, Simone Wagner, Jürgen Haas, Roland Kehm, Johann Sellner, Werner Hacke, Uta Meyding-Lamadé.   

Abstract

Herpes simplex virus encephalitis (HSVE) causes elevated morbidity and mortality despite antiviral treatment. Virus-independent mechanisms may perpetuate brain damage. Matrix metalloproteinases (MMPs) target extracellular matrix components. This study describes the protein and mRNA expression of MMP2 and MMP9 in experimental HSVE in the short and long term. Ten SJL-NBOM mice were infected with neurovirulent HSV-1 and compared with nine controls. The presence of MMP2 and MMP9 in brain tissue was analyzed with sodium-dodecyl-sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) gelatin zymography and mRNA expression of MMP2 and MMP9 with quantitative real-time PCR at days 7, 21 and 180 post-inoculation. Infected animals had a significantly elevated gelatinolytic activity of MMP2 at all time points, and of MMP9 at days 21 and 180. Increased presence of MMP2 and MMP9 in chronic HSVE may contribute to ongoing damage. Inhibition of MMP2 and MMP9 might be a suitable target for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364410     DOI: 10.1016/j.neulet.2004.06.064

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  9 in total

1.  Japanese encephalitis virus induces matrix metalloproteinase-9 in rat brain astrocytes via NF-κB signalling dependent on MAPKs and reactive oxygen species.

Authors:  Wei-Hsuan Tung; Hsin-Wen Tsai; I-Ta Lee; Hsi-Lung Hsieh; Wei-June Chen; Yuh-Lien Chen; Chuen-Mao Yang
Journal:  Br J Pharmacol       Date:  2010-12       Impact factor: 8.739

Review 2.  Mechanisms of Blood-Brain Barrier Disruption in Herpes Simplex Encephalitis.

Authors:  Hui Liu; Ke Qiu; Qiang He; Qiang Lei; Wei Lu
Journal:  J Neuroimmune Pharmacol       Date:  2018-11-19       Impact factor: 4.147

3.  Aquaporin 4 regulation during acute and long-term experimental Herpes simplex virus encephalitis.

Authors:  F J Martinez Torres; D Völcker; N Dörner; Th Lenhard; S Nielsen; J Haas; K Kiening; U Meyding-Lamadé
Journal:  J Neurovirol       Date:  2007       Impact factor: 2.643

4.  The alterations of matrix metalloproteinase-9 in mouse brainstem during herpes simplex virus type 1-induced facial palsy.

Authors:  Dong Chen; Daogong Zhang; Lei Xu; Yuechen Han; Haibo Wang
Journal:  J Mol Neurosci       Date:  2013-07-02       Impact factor: 3.444

5.  The Innate Immune Response to Herpes Simplex Virus 1 Infection Is Dampened in the Newborn Brain and Can Be Modulated by Exogenous Interferon Beta To Improve Survival.

Authors:  Daniel Giraldo; Douglas R Wilcox; Richard Longnecker
Journal:  mBio       Date:  2020-05-26       Impact factor: 7.867

6.  The German trial on Aciclovir and Corticosteroids in Herpes-simplex-virus-Encephalitis (GACHE): a multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  U Meyding-Lamadé; C Jacobi; F Martinez-Torres; T Lenhard; B Kress; M Kieser; C Klose; K Einhäupl; J Bösel; M-B Mackert; V Homberg; C Koennecke; G Weißheit; D Claus; B Kieseier; J Bardutzky; T Neumann-Haefelin; M W Lorenz; H Steinmetz; C Gerloff; D Schneider; A Grau; M Klein; R Dziewas; U Bogdahn; W Jakob; R Linker; K Fuchs; A Sander; S Luntz; T Hoppe-Tichy; D F Hanley; R von Kummer; E Craemer
Journal:  Neurol Res Pract       Date:  2019-09-12

7.  Asymptomatic Herpes Simplex Virus Type 1 Infection Causes an Earlier Onset and More Severe Experimental Autoimmune Encephalomyelitis.

Authors:  Luisa F Duarte; María J Altamirano-Lagos; Jorge H Tabares-Guevara; Ma Cecilia Opazo; Máximo Díaz; Romina Navarrete; Catalina Muza; Omar P Vallejos; Claudia A Riedel; Susan M Bueno; Alexis M Kalergis; Pablo A González
Journal:  Front Immunol       Date:  2021-02-15       Impact factor: 7.561

8.  Mendelian Randomization Analysis Suggests No Associations of Herpes Simplex Virus Infections With Multiple Sclerosis.

Authors:  Wan Zhang; Pengfei Wu; Rui Yin; Meichen Sun; Rongsen Zhang; Xiaoyao Liao; Yuhong Lin; Hui Lu
Journal:  Front Neurosci       Date:  2022-03-01       Impact factor: 4.677

9.  Protocol for German trial of Acyclovir and corticosteroids in Herpes-simplex-virus-encephalitis (GACHE): a multicenter, multinational, randomized, double-blind, placebo-controlled German, Austrian and Dutch trial [ISRCTN45122933].

Authors:  Francisco Martinez-Torres; Sanjay Menon; Maria Pritsch; Norbert Victor; Ekkehart Jenetzky; Katrin Jensen; Eva Schielke; Erich Schmutzhard; Jan de Gans; Chin-Hee Chung; Steffen Luntz; Werner Hacke; Uta Meyding-Lamadé
Journal:  BMC Neurol       Date:  2008-10-29       Impact factor: 2.474

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.